GlassScriptPhysician profile
Georges Junior Joseph
NPI 1548555956
$15,450.50
in general payments reported to CMS, 2019-2025
37 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $1,663 · 2021: $1,379 · 2022: $2,216 · 2023: $2,747 · 2024: $3,070 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,430 · Travel and Lodging: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,430.04 |
| Travel and Lodging | $854.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,927.82 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Brady, General - Therapies |
| Abbott Laboratories | $2,656.34 | 2019-2025 | Aveir, Navitor, Cardiomems |
| Medtronic, INC. | $2,355.37 | 2021-2025 | Micra, Corevalve Evolut R, Reveal Linq |
| Abiomed | $1,094.85 | 2020-2025 | Impella |
| Edwards Lifesciences Corporation | $984.32 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inari Medical, INC. | $771.42 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.61 | 2019-2025 | Jardiance |
| Cardiovascular Systems INC. | $596.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $485.76 | 2019-2023 | Brilinta |
| Janssen Pharmaceuticals, INC | $393.88 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $341.94 | 2023-2025 | Lifevest |
| Amgen INC. | $314.76 | 2020-2024 | Repatha |
| Esperion Therapeutics, INC. | $229.62 | 2021-2024 | Nexletol, Nexlizet |
| Pfizer INC. | $208.87 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.89 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $145.77 | 2024 | Inpefa |
| Atricure, INC. | $135.60 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Medtronic Vascular, INC. | $133.75 | 2019 | |
| Corcept Therapeutics | $102.18 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $79.53 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $79.17 | 2019-2023 | Livalo |
| Actelion Pharmaceuticals US, INC. | $69.39 | 2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $59.20 | 2023 | Arcalyst |
| Cardiva Medical, INC. | $48.91 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Kestra Medical Technology Services, INC. | $48.71 | 2023-2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $47.92 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $46.41 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.13 | 2021-2025 | Eliquis |
| Elutia, INC. | $33.96 | 2020 | |
| Merck Sharp & Dohme LLC | $33.81 | 2022-2023 | Verquvo |
| Stryker Corporation | $32.04 | 2025 | Flowtriever |
| Scpharmaceuticals INC. | $30.81 | 2025 | |
| Astellas Pharma US INC | $29.98 | 2019-2020 | |
| Cleerly, INC. | $24.09 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Novo Nordisk INC | $16.35 | 2024 | Ozempic |
| Cardinal Health 200 LLC | $13.45 | 2020 | |
| Biosense Webster, INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.